Your browser doesn't support javascript.
Serum IL-28A/IFN-λ2 is linked to disease severity of COVID-19.
Fukuda, Yosuke; Homma, Tetsuya; Inoue, Hideki; Goto, Yuiko; Sato, Yoko; Ikeda, Hitoshi; Onitsuka, Chisato; Sato, Hiroki; Akimoto, Kaho; Ebato, Takaya; Suganuma, Hiromitsu; Kawahara, Tomoko; Mikuni, Hatsuko; Uchida, Yoshitaka; Suzuki, Shintaro; Tanaka, Akihiko; Sagara, Hironori.
  • Fukuda Y; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Homma T; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan. oldham726@yahoo.co.jp.
  • Inoue H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Goto Y; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Sato Y; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Ikeda H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Onitsuka C; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Sato H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Akimoto K; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Ebato T; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Suganuma H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Kawahara T; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Mikuni H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Uchida Y; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Suzuki S; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Tanaka A; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
  • Sagara H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, 142-8666, Japan.
Sci Rep ; 12(1): 5458, 2022 03 31.
Article in English | MEDLINE | ID: covidwho-1931453
ABSTRACT
Type III interferons (IFNs) play an important role in respiratory viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to determine whether the expression of serum type III IFNs predicted disease severity among patients with the coronavirus disease (COVID-19). A retrospective cohort study was conducted of patients admitted to a single hospital between March 21, 2020, and March 31, 2021. Patients were divided into mild to moderate I (MM) and moderate II to severe (MS) groups based on the COVID-19 severity classification developed by the Japanese Ministry of Health, Labor and Welfare. A total of 257 patients were included in the analysis. Human interleukin-28A (IL-28A/IFN-λ2) expression was significantly lower, and interleukin (IL)-6 expression was significantly higher in the MS group than in the MM group (both p < 0.001). In addition, IL-28A/IFN-λ2 was statistically significantly inversely correlated with the time from disease onset to negative SARS-CoV-2 PCR results (p = 0.049). Multivariable logistic regression analysis showed that IL-28A/IFN-λ2 was an independent predictor of disease severity (p = 0.021). The low expression of IL-28A/IFN-λ2 may serve as a serum biomarker that predicts the severity of COVID-19, possibly through the mechanism of delayed viral elimination.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukins / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-09544-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukins / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-09544-8